Clinical outcome of recurrent locally advanced cervical cancer (LACC) submitted to primary multimodality therapies

被引:55
|
作者
Legge, F. [1 ]
Chiantera, V. [2 ]
Macchia, G. [3 ]
Fagotti, A. [4 ]
Fanfani, F. [5 ]
Ercoli, A. [6 ]
Gallotta, V. [5 ]
Morganti, A. G. [3 ]
Valentini, V. [7 ]
Scambia, G. [5 ]
Ferrandina, G. [5 ]
机构
[1] F Miulli Gen Reg Hosp, Gynecol Oncol Unit, I-70021 Bari, Italy
[2] Giovanni Paolo II Fdn, Gynecol Oncol Unit, Campobasso, Italy
[3] Giovanni Paolo II Fdn, Dept Radiat Therapy, Campobasso, Italy
[4] Univ Perugia, Gynecol Surg Unit, I-06100 Perugia, Italy
[5] Univ Cattolica Sacro Cuore, Gynecol Oncol Unit, Rome, Italy
[6] Policlin Abano Terme, Gynecol Oncol Unit, Padua, Italy
[7] Univ Cattolica Sacro Cuore, Dept Radiat Therapy, Rome, Italy
关键词
Recurrent cervical cancer; Chemoradiation; Radical hysterectomy; Post-relapse survival; Prognosis; PELVIC EXENTERATION; CONCOMITANT CHEMORADIATION; COMPLETION SURGERY; PHASE-III; CARCINOMA; SURVIVAL; CHEMORADIOTHERAPY; HYSTERECTOMY;
D O I
10.1016/j.ygyno.2015.04.035
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives. Recurrence of disease represents a clinical challenge in cervical cancer patients, especially when all available treatment modalities have been used in the primary setting. The aim of this study was to analyze the patterns of recurrence and their association with clinical outcome in locally advanced cervical cancer (LACC) patients submitted to primary chemoradiation (CTRT) followed by radical surgery (RS). Methods. This study was conducted on 364 LACC patients treated with CTRT plus RS since January 1996 to July 2012. For each relapse, information on date of clinical/pathological recurrence, and pattern of disease presentation were retrieved. Post-relapse survival (PRS) was recorded from the date of recurrence to the date of death for disease or last seen. Survival probabilities were compared by the log rank test. Cox's regression model with stepwise variable selection was used for multivariate prognostic analysis for PRS. Results. Within a median follow-up of 42 months, 75 recurrences (20.6%) and 54 disease-associated deaths (14.8%) were recorded. By analysing the pattern of relapse, most of the recurrences were outside the irradiated field (n = 43,57.3%) and the most frequently observed site was visceral (n = 16,213%). Among the parameters of the recurrence associated with PRS including the pattern of recurrence, the size of recurrence, SCC-Ag serum levels at recurrence, and secondary radical surgery, only the last one retained an independent predictive role in reducing the risk of death (p = 0.037). Conclusions. The feasibility of secondary radical resection positively impacts on PRS of LACC patients submitted to multimodality primary treatments. (C) 2015 Elsevier Inc. All rights reserved.
引用
收藏
页码:83 / 88
页数:6
相关论文
共 50 条
  • [21] Clinical outcome of interstitial pulsed dose rate brachytherapy in multimodality treatment of locally advanced primary or recurrent rectal and sigmoid cancer with high risk of incomplete microscopic resection
    Nielsen, Mette Bak
    Rasmussen, Peter Christian
    Tanderup, Kari
    Nielsen, Soren Kynde
    Fokdal, Lars
    Laurberg, Soren
    Lindegaard, Jacob Christian
    [J]. ACTA ONCOLOGICA, 2016, 55 (12) : 1408 - 1413
  • [22] Clinical outcome of pelvic exenteration in patients with advanced or recurrent uterine cervical cancer
    Sota Tanaka
    Satoru Nagase
    Michiko Kaiho-Sakuma
    Tomoyuki Nagai
    Hiroki Kurosawa
    Masafumi Toyoshima
    Hideki Tokunaga
    Takeo Otsuki
    Hiroki Utsunomiya
    Tadao Takano
    Hitoshi Niikura
    Kiyoshi Ito
    Nobuo Yaegashi
    [J]. International Journal of Clinical Oncology, 2014, 19 : 133 - 138
  • [23] Clinical outcome of pelvic exenteration in patients with advanced or recurrent uterine cervical cancer
    Tanaka, Sota
    Nagase, Satoru
    Kaiho-Sakuma, Michiko
    Nagai, Tomoyuki
    Kurosawa, Hiroki
    Toyoshima, Masafumi
    Tokunaga, Hideki
    Otsuki, Takeo
    Utsunomiya, Hiroki
    Takano, Tadao
    Niikura, Hitoshi
    Ito, Kiyoshi
    Yaegashi, Nobuo
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2014, 19 (01) : 133 - 138
  • [24] LOCALLY ADVANCED CERVICAL CARCINOMA (LACC) SUBMITTED TO CHEMIORADIATION FOLLOWED BY SURGERY: A PROPENSITY SCORE ANALYSIS OF RESPONSE AND SURVIVAL ACCORDING TO HISTOTYPE
    Legge, F.
    Murgia, F.
    Gallotta, V.
    Fanfani, F.
    Ercoli, A.
    Cosentino, F.
    Carone, V.
    Turco, L. C.
    Chiantera, V.
    Anchora, L. Pedone
    Bizzarri, N.
    Macchia, G.
    Valentini, V.
    Scambia, G.
    Ferrandina, G.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A62 - A62
  • [25] Weekly carboplatin and docetaxel for locally advanced primary and recurrent cervical cancer:: A phase I study
    Rein, DT
    Kurbacher, CM
    Breidenbach, M
    Schöndorf, T
    Schmidt, T
    König, E
    Göhring, UJ
    Blohmer, JU
    Mallmann, P
    [J]. GYNECOLOGIC ONCOLOGY, 2002, 87 (01) : 98 - 103
  • [26] The Mayo Clinic experience with multimodality treatment of locally advanced or recurrent colon cancer
    Taylor, WE
    Donohue, JH
    Gunderson, LL
    Nelson, H
    Nagorney, DM
    Devine, RM
    Haddock, MG
    Larson, DR
    Rubin, J
    O'Connell, MJ
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2002, 9 (02) : 177 - 185
  • [27] The mayo clinic experience with multimodality treatment of locally advanced or recurrent colon cancer
    William E. Taylor
    John H. Donohue
    Leonard L. Gunderson
    Heidi Nelson
    David M. Nagorney
    Richard M. Devine
    Michael G. Haddock
    Dirk R. Larson
    Joseph Rubin
    Michael J. O’Connell
    [J]. Annals of Surgical Oncology, 2002, 9 (2) : 177 - 185
  • [28] The role of chemotherapy in locally advanced, metastatic and recurrent cervical cancer
    Tambaro, R
    Scambia, G
    Di Maio, M
    Pisano, C
    Barletta, E
    Iaffaioli, VR
    Pignata, S
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2004, 52 (01) : 33 - 44
  • [29] Current controversies in systemic therapies for advanced or recurrent cervical cancer
    Chan, Jack Junjie
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1358 - S1358
  • [30] Clinical trials for advanced or recurrent cervical cancer
    Kim, Jae-Weon
    Kim, Se Ik
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1358 - S1358